Middle East & Africa Biopharmaceuticals Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)

No. of Pages: 230    |    Report Code: BMIRE00028623    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Middle East & Africa Biopharmaceuticals Market

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Middle East & Africa Biopharmaceuticals Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Middle East & Africa Biopharmaceuticals Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Advancements in gene therapies
  • 5.1.2 Rising demand for personalized medicine
  • 5.1.3 Growth in biologic drug development
5.2 Market Opportunities
  • 5.2.1 Rising demand for biologics in treating chronic diseases
  • 5.2.2 Expanding market for targeted therapies
  • 5.2.3 Growth in gene and cell therapies
5.3 Future Trends
  • 5.3.1 Expansion of biologics for treating rare and chronic diseases
  • 5.3.2 Growing adoption of biologic drugs in oncology and immunology
  • 5.3.3 Advancements in genetic and cell-based therapies
5.4 Impact of Drivers and Restraints

6. Middle East & Africa Biopharmaceuticals Market Regional Analysis

6.1 Middle East & Africa Biopharmaceuticals Market Overview
6.2 Middle East & Africa Biopharmaceuticals Market Revenue 2020-2028 (US$ Billion)
6.3 Middle East & Africa Biopharmaceuticals Market Forecast Analysis

7. Middle East & Africa Biopharmaceuticals Market Analysis – by Product Type

7.1 Monoclonal Antibodies
  • 7.1.1 Overview
  • 7.1.2 Monoclonal Antibodies: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.2 Recombinant Vaccines
  • 7.2.1 Overview
  • 7.2.2 Recombinant Vaccines: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.3 Conventional Vaccines
  • 7.3.1 Overview
  • 7.3.2 Conventional Vaccines: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.4 Recombinant Growth Factors
  • 7.4.1 Overview
  • 7.4.2 Recombinant Growth Factors: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.5 Purified Proteins
  • 7.5.1 Overview
  • 7.5.2 Purified Proteins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.6 Recombinant Proteins
  • 7.6.1 Overview
  • 7.6.2 Recombinant Proteins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.7 Recombinant Hormones
  • 7.7.1 Overview
  • 7.7.2 Recombinant Hormones: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.8 Recombinant Enzymes
  • 7.8.1 Overview
  • 7.8.2 Recombinant Enzymes: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.9 Cell & Gene Therapies
  • 7.9.1 Overview
  • 7.9.2 Cell & Gene Therapies: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)
7.10 Cytokines/Interferon/Interleukins
  • 7.10.1 Overview
  • 7.10.2 Cytokines/Interferon/Interleukins: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2031 (US$ Billion)

8. Middle East & Africa Biopharmaceuticals Market Analysis – by Application

8.1 Oncology
  • 8.1.1 Overview
  • 8.1.2 Oncology: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.2 Inflammatory & Infectious Disease
  • 8.2.1 Overview
  • 8.2.2 Inflammatory & Infectious Disease: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.3 Autoimmune Disorders
  • 8.3.1 Overview
  • 8.3.2 Autoimmune Disorders: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.4 Metabolic Disorders
  • 8.4.1 Overview
  • 8.4.2 Metabolic Disorders: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.5 Hormonal Disorders & Growth Failure
  • 8.5.1 Overview
  • 8.5.2 Hormonal Disorders & Growth Failure: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.6 Cardiovascular Diseases
  • 8.6.1 Overview
  • 8.6.2 Cardiovascular Diseases: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
8.7 Neurological Diseases
  • 8.7.1 Overview
  • 8.7.2 Neurological Diseases: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)

9. Middle East & Africa Biopharmaceuticals Market – Middle East and Africa Analysis

9.1 Middle East and Africa
  • 9.1.1 Middle East & Africa Biopharmaceuticals Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 9.1.1.1 Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast Analysis – by Country
  • 9.1.1.1 South Africa: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
    • 9.1.1.1.1 South Africa: Middle East & Africa Biopharmaceuticals Market Breakdown, by Product Type
    • 9.1.1.1.2 South Africa: Middle East & Africa Biopharmaceuticals Market Breakdown, by Application
  • 9.1.1.2 Saudi Arabia: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
    • 9.1.1.2.1 Saudi Arabia: Middle East & Africa Biopharmaceuticals Market Breakdown, by Product Type
    • 9.1.1.2.2 Saudi Arabia: Middle East & Africa Biopharmaceuticals Market Breakdown, by Application
  • 9.1.1.3 UAE: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
    • 9.1.1.3.1 UAE: Middle East & Africa Biopharmaceuticals Market Breakdown, by Product Type
    • 9.1.1.3.2 UAE: Middle East & Africa Biopharmaceuticals Market Breakdown, by Application
  • 9.1.1.4 Rest of Middle East and Africa: Middle East & Africa Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Billion)
    • 9.1.1.4.1 Rest of Middle East and Africa: Middle East & Africa Biopharmaceuticals Market Breakdown, by Product Type
    • 9.1.1.4.2 Rest of Middle East and Africa: Middle East & Africa Biopharmaceuticals Market Breakdown, by Application

10. Competitive Landscape

10.1 Heat Map Analysis
10.2 Company Positioning and Concentration

11. Middle East & Africa Biopharmaceuticals Market Industry Landscape

11.1 Overview
11.2 Mergers and Acquisitions
11.3 Agreements, Collaborations, and Joint Ventures
11.4 New Product Launches
11.5 Expansions and Other Strategic Developments

12. Company Profiles

12.1 AbbVie Inc
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
12.2 AGC Biologics AS
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
12.3 Amgen Inc
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
12.4 Boehringer Ingelheim International GmbH
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
12.5 Bristol-Myers Squibb Co
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
12.6 Eli Lilly and Co
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
12.7 Johnson & Johnson
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
12.8 Lonza Group AG
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
12.9 Thermo Fisher Scientific Inc
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments

13. Appendix

13.1 About Business Market Insights

The List of Companies - M Market

  1. AbbVie Inc           
  2. AGC Biologics AS                                       
  3. Amgen Inc           
  4. Boehringer Ingelheim International GmbH   
  5. Bristol-Myers Squibb Co     
  6. Eli Lilly and Co     
  7. Johnson & Johnson           
  8. Lonza Group AG                                        
  9. Thermo Fisher Scientific Inc